 double-blind randomized trial ketotifen versus placebo early diffuse scleroderma efficacy mast cell-stabilizing drug ketotifen scleroderma prospective double-blind placebo-controlled trial patients significant improvement clinical parameters pulmonary function global assessments cell releasability Pruritus group active drug Six months treatment ketotifen mg/day apparent benefit patients early scleroderma unable role mast cells scleroderma mast cell suppression